Watch for the FDA Type C meeting outcome and the pace of LEVEL-2 protocol amendment implementation at sites. The enrichment strategy is data-driven but still unproven; protocol design paper publication in Q1 2027 is the next binary catalyst.
Price Chart
Executive Summary
Tenax Therapeutics filed an 8-K announcing a temporary pause in enrollment of its Phase 3 LEVEL-2 trial of TNX-103 (oral levosimendan) for PH-HFpEF, while it amends the protocol to enrich for patients with higher disease burden based on Phase 3 LEVEL trial findings. The company has also requested a Type C meeting with the FDA to discuss the overall development program. The filing includes an investor presentation detailing the data-driven enrichment strategy and confirming the company is funded through Q2 2028.
Key Facts
- Tenax has temporarily paused enrollment in the Phase 3 LEVEL-2 trial to implement a protocol amendment with stricter entry criteria.
- The amended LEVEL-2 entry criteria are: [100m ≤ 6MWD ≤ 300m] OR [300m < 6MWD ≤ 400m AND RAVI ≥ 25 mL/m²].
- In LEVEL patients meeting these criteria, TNX-103 showed a >34-meter placebo-adjusted improvement in 6MWD at Week 12 (95% CI: +15m, +53m; nominal p=0.001).
- The company has requested a Type C meeting with the FDA to discuss the overall development of levosimendan in PH-HFpEF.
- The company states it is funded through Q2 2028.
- The Phase 3 LEVEL trial did not meet its primary endpoint of change in 6MWD in the overall population (treatment difference 3.5m, p=0.63).
- In a prespecified subgroup with baseline 6MWD <333m, TNX-103 showed a +26.3m improvement vs placebo (95% CI: 6.0, 46.7; nominal p=0.0112).
- NT-proBNP was reduced by 49% vs placebo in the overall population (nominal p<0.0001).
- The enrollment pause is not safety-related and was not made in response to any regulatory authority request.
- US patents for oral (TNX-103), IV, expanded dose, and combination use extend through 2040.
Financial Impact
No new financial data provided; company funded through Q2 2028; no revenue or earnings reported.
Risk Factors
- Risk that the FDA may not agree with the company's interpretation of LEVEL data or the enrichment strategy for LEVEL-2.
- Risk that the enriched population in LEVEL-2 may not replicate the LEVEL subgroup results.
- Risk that the temporary enrollment pause delays the trial timeline.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-417939 |
| Document: d139658d8k.htm | 0001193125-26-417939 |
| Document: 0001193125-26-417939-index-headers.html | 0001193125-26-417939 |
| Document: 0001193125-26-417939-index.html | 0001193125-26-417939 |
| Document: 0001193125-26-417939.txt | 0001193125-26-417939 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.64 (+20.59%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.64 (+2.50%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.64 (−10.38%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.64 (−12.30%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.64 (−13.68%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.64 (−23.00%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.64 (−10.87%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.64 (−88.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers